IL307465A - Combination therapies for the treatment of cancer - Google Patents
Combination therapies for the treatment of cancerInfo
- Publication number
- IL307465A IL307465A IL307465A IL30746523A IL307465A IL 307465 A IL307465 A IL 307465A IL 307465 A IL307465 A IL 307465A IL 30746523 A IL30746523 A IL 30746523A IL 307465 A IL307465 A IL 307465A
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- treatment
- combination therapies
- therapies
- combination
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172593P | 2021-04-08 | 2021-04-08 | |
| PCT/US2022/017902 WO2022216379A1 (en) | 2021-04-08 | 2022-02-25 | Combination therapies for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL307465A true IL307465A (en) | 2023-12-01 |
Family
ID=83546373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307465A IL307465A (en) | 2021-04-08 | 2022-02-25 | Combination therapies for the treatment of cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220331330A1 (en) |
| EP (1) | EP4319750A1 (en) |
| JP (1) | JP2024516353A (en) |
| KR (1) | KR20240004476A (en) |
| CN (1) | CN117120054A (en) |
| AU (1) | AU2022254933A1 (en) |
| BR (1) | BR112023020669A2 (en) |
| CA (1) | CA3214747A1 (en) |
| IL (1) | IL307465A (en) |
| MX (1) | MX2023011790A (en) |
| WO (1) | WO2022216379A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ722019A (en) | 2014-01-13 | 2022-07-01 | Aurigene Discovery Tech Ltd | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36660A (en) * | 2015-04-30 | 2016-11-30 | Bayer Pharma AG | IRAK4 INHIBITORS COMBINATIONS |
| AU2016293446A1 (en) * | 2015-07-15 | 2018-02-15 | Aurigene Discovery Technologies Limited | Substituted aza compounds as IRAK-4 inhibitors |
| WO2018178947A2 (en) * | 2017-03-31 | 2018-10-04 | Aurigene Discovery Technologies Limited | Compounds and compositions for treating hematological disorders |
| AU2018359248B2 (en) * | 2017-10-31 | 2023-06-01 | Curis, Inc. | Compounds and compositions for treating hematological disorders |
| MX2021006154A (en) * | 2018-11-30 | 2021-08-24 | Kymera Therapeutics Inc | Irak degraders and uses thereof. |
| CN114502158A (en) * | 2019-06-28 | 2022-05-13 | 凯麦拉医疗公司 | IRAK degradation agent and application thereof |
-
2022
- 2022-02-25 CN CN202280027196.6A patent/CN117120054A/en active Pending
- 2022-02-25 AU AU2022254933A patent/AU2022254933A1/en active Pending
- 2022-02-25 EP EP22785128.4A patent/EP4319750A1/en active Pending
- 2022-02-25 WO PCT/US2022/017902 patent/WO2022216379A1/en active Application Filing
- 2022-02-25 JP JP2023561748A patent/JP2024516353A/en active Pending
- 2022-02-25 MX MX2023011790A patent/MX2023011790A/en unknown
- 2022-02-25 IL IL307465A patent/IL307465A/en unknown
- 2022-02-25 BR BR112023020669A patent/BR112023020669A2/en unknown
- 2022-02-25 US US17/680,995 patent/US20220331330A1/en active Pending
- 2022-02-25 KR KR1020237038312A patent/KR20240004476A/en unknown
- 2022-02-25 CA CA3214747A patent/CA3214747A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022254933A1 (en) | 2023-11-09 |
| CN117120054A (en) | 2023-11-24 |
| WO2022216379A1 (en) | 2022-10-13 |
| JP2024516353A (en) | 2024-04-15 |
| BR112023020669A2 (en) | 2023-12-12 |
| EP4319750A1 (en) | 2024-02-14 |
| WO2022216379A8 (en) | 2024-02-29 |
| KR20240004476A (en) | 2024-01-11 |
| US20220331330A1 (en) | 2022-10-20 |
| CA3214747A1 (en) | 2022-10-13 |
| MX2023011790A (en) | 2023-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281256A (en) | Combination therapy for the treatment of triple-negative breast cancer | |
| IL267795A (en) | Combination therapy for the treatment of cancer | |
| ZA202206743B (en) | Therapy for the treatment of cancer | |
| IL280337A (en) | Lag-3 combination therapy for the treatment of cancer | |
| IL274837B1 (en) | Combination therapy for the treatment of cancer | |
| EP4259639A4 (en) | Combination therapies for the treatment of cancer | |
| EP4259638A4 (en) | Combination therapies for the treatment of cancer | |
| IL281845A (en) | Combination therapy for the treatment of cancer | |
| IL290011A (en) | Ezh2 inhibition in combination therapies for the treatment of cancers | |
| IL284162A (en) | Combination therapy for the treatment of cancer | |
| EP4010081A4 (en) | Combination therapy for treatment of cancer | |
| IL266993A (en) | Combination therapy for the treatment of cancer | |
| IL308400A (en) | Combination therapies for treating cancer | |
| EP4259147A4 (en) | Combination therapies for the treatment of cancer | |
| IL281439A (en) | Combination therapy for treating blood cancer | |
| IL307964A (en) | Combination therapy for cancer treatment | |
| IL281281A (en) | Combination therapy for the treatment of prostate cancer | |
| IL307465A (en) | Combination therapies for the treatment of cancer | |
| IL286353A (en) | Combinations of iadademstat for cancer therapy | |
| IL275981A (en) | Combination therapies for the treatment of breast cancer | |
| SG11202100571TA (en) | Anti-lypd3 car t-cell therapy for the treatment of cancer | |
| IL253642A0 (en) | Combination therapy for the treatment of cancer | |
| IL305780A (en) | Methods for the treatment of cancer | |
| IL315250A (en) | Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer | |
| IL281782A (en) | Pharmaceutical combination for the treatment of cancer |